Katya Moreno

Therapeutic Area Head Hematology and Global Product Development / Medical Affairs
F. Hoffmann-La Roche Ltd

Presentation(s):

• PB0670 - Bleed Outcomes in the Moderate and Mild Hemophilia A Population Without Prophylactic Treatment in CHESS II and CHESS PAEDs

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0674 - Annualized Bleed Rates in Severe Hemophilia A After Switch to Emicizumab Based on CHESS II Data, Including an Oversample of Emicizumab Patients

  Monday, July 11, 2022
  6:30 PM – 7:30 PM